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Polymorphisms in the NOS1AP Gene
Modulate QT Interval Duration and Risk
of Arrhythmias in the Long QT Syndrome
Marta Toma´s, PHD,*† Carlo Napolitano, MD, PHD,*‡ Luciana De Giuli, PHD,* Raffaella Bloise, MD,*
Isaac Subirana, MS,†§ Alberto Malovini, MS,# Riccardo Bellazzi, PHD, Dan E. Arking, PHD,**
Eduardo Marban, MD, PHD,‡‡ Aravinda Chakravarti, PHD,** Peter M. Spooner, PHD,††
Silvia G. Priori, MD, PHD*‡¶
Pavia and Milan, Italy; Barcelona, Spain; New York, New York; Baltimore, Maryland;
and Los Angeles, California
Objectives We investigated the role of nitric oxide 1 adaptor protein (NOS1AP) as a genetic modifier of long QT syndrome
(LQTS).
Background LQTS risk stratification is complicated by the phenotype variability that limits prediction of life-threatening ar-
rhythmic events based on available metrics. Thus, the identification of new markers is desirable. Recent studies
have shown that NOS1AP variations in the gene modulate QT interval in healthy and 1 LQTS kindred, and occur-
rence of cardiac events in healthy subjects.
Methods The study included 901 patients enrolled in a prospective LQTS registry. Three NOS1AP marker SNPs
(rs4657139, rs16847548, and rs10494366) were genotyped to assess the effect of variant alleles on QTc and
on the incidence of cardiac events. We quantified the association between variant alleles, QTc, and outcomes to
assess whether NOS1AP is a useful risk stratifier in LQTS.
Results Variant alleles tagged by SNPs rs4657139 and rs16847548 were associated with an average QTc prolongation
of 7 and 8 ms, respectively (p  0.05; p  0.01); whereas rs4657139 and rs10494366 were associated with
increased incidence of cardiac events (25.2% vs. 18.0%, p  0.05 and 24.8% vs. 17.8% p  0.05). Cox multivar-
iate analysis identified rs10494366 minor allele as an independent prognostic marker among patients with QTc
500 ms (hazard ratio: 1.63; 95% confidence interval: 1.06 to 2.5; p  0.05) but not in the entire cohort.
Conclusions Our results provide the first demonstration, to our knowledge, of a risk-conferring genetic modifier in a large
LQTS cohort. Subject to confirmation in additional cohorts, we suggest that the NOS1AP tag SNP genotype may
provide an additional clinical dimension, which helps assess risk and choice of therapeutic strategies in
LQTS. (J Am Coll Cardiol 2010;55:2745–52) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.065(
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tong QT syndrome (LQTS) is a genetic disorder caused by
utations that affect genes encoding ion-channel subunits
r proteins that indirectly modulate the function of ion
hannels. The disease derives its name from the diagnostic
lectrocardiographic feature of prolonged repolarization
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death (SCD) and in those who
continue to have cardiac events
despite antiadrenergic therapy
(2). The identification of markers
of increased arrhythmic risk is a
major goal of epidemiological re-
search in LQTS. In addition to
extent of QT prolongation, the
major prognostic indicators (3),
sex and genetic locus, have also
proven useful in predicting ad-
verse events (4,5). More recently,
the effort to account for the large
phenotypic variability of the dis-
ease (6) has focused on the search
for additional genetic modifiers.
Polymorphisms at additional loci
in LQTS genes have been pro-
posed as factors that may modu-
ate QT interval (7); however, conclusive evidence that 1 or
ore polymorphisms influence the phenotype, including
isk of cardiac events, of the disease is lacking.
Recently, a genome-wide association study identified an
ssociation between single nucleotide polymorphisms
SNPs) in the nitric oxide 1 adaptor protein (NOS1AP) gene
nd QT interval (8). The QT-modifying influence of
OS1AP SNPs was subsequently replicated in follow-up
tudies on the Framingham Heart and Rotterdam popula-
ions (9,10) as well as in other cohorts (11–16). Recently,
he role of NOS1AP gene variants in sudden cardiac death
as been reported in the general population (17), but the
ole of variants within this gene in modulating susceptibility
o cardiac events in LQTS patients is only beginning to be
ssessed (18,19).
Here, we assessed a large cohort of LQTS patients to
ddress whether: 1) polymorphisms of the NOS1AP gene
odulate the duration of QT interval in LQTS; and 2)
OS1AP SNPs are independent predictors of risk of cardiac
vents in LQTS patients and may therefore contribute to
isk stratification.
ethods
tudy population. From our clinical database and DNA
ank of LQTS patients (4–6), we identified Caucasian indi-
iduals with a clinical and/or molecular diagnosis of Romano-
ard LQTS who had been screened for mutations in the
CNQ1, KCNH2, KCNE1, KCNE2, and SCN5A genes
4–6) and for whom we had DNA and clinical data
vailable on natural history, cardiac events, and response to
herapy. Nine-hundred and one affected patients entered
he study: 520 probands and 381 family members (216
rst-degree relatives from 153 families). Families with more
Abbreviations
and Acronyms
CI  confidence interval
ECG  electrocardiogram
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LQTS  long QT syndrome
MAF  minor allele
frequency
NOS1AP  nitric oxide 1
adaptor protein
PCR  polymerase chain
reaction
SCD  sudden cardiac
death
SNP  single nucleotide
polymorphismhan 1 mutation were excluded. bLocal and national laws regarding biomedical research,
ersonal data protection, and confidentiality were respected.
he study protocol was approved by the Maugeri Foundation
thical Committee, and all participants or their legal guardians
igned an informed consent.
efinitions. QT interval was measured at the enrollment
lectrocardiogram (ECG). Heart rate QT correction was
erformed (QTc) in lead II (or lead I or III if it could not be
easured in lead II) (4–6) from 12-lead ECGs with the use of
azett’s formula during stable heart rate (4–6). Based on
revious studies (4,5), we used the QTc cutoff of 500 ms to
efine high-risk patients. Cardiac events were defined as
yncope, torsade de pointes, cardiac arrest, or ICD shocks (4).
s previously done in our studies (4–6), we used an observa-
ion period for cardiac events from birth to either attainment of
ge 40 years or the initiation of antiadrenergic therapy (beta-
lockers or left cardiac sympathetic denervation). Symptomatic
atients are considered those who experienced a cardiac event
ccording to the preceding definitions.
On the basis of a recent report (17), we genotyped 3
olymorphisms (rs4657139, rs16847548, and rs10494366)
ocated within the high linkage disequilibrium block in the
= region of the NOS1AP gene (8); 3 SNPs (rs4657139,
s16847548, and rs10494366) showed minor allele fre-
uency (MAF) 0.10 and were included in this analysis.
NPs and haplotypes are indicated by an uppercase “A” to
efer to the “major” (common) allele and a lower case “a” to
efer to the “minor” (rare) allele. We have compared
hether the dominant, additive, or recessive model fitted
etter in order to predict QT or cardiac events. To do this,
e performed linear and logistic regression for QT and
ardiac events, respectively, taking the SNP as the predictor
ariable in a dominant (2 categories: AA vs. Aa or aa),
dditive (3 categories: AA vs. Aa vs. aa and treated as
ontinuous variables), or recessive (2 categories: AA or Aa
s. aa). After estimating the model, the model with highest
ikelihood was chosen: the largest R2 for linear model and
he Nagelkerke’s pseudo-R2 for the logistic regression model.
his analysis showed that the dominant model for QTc
eached the best fit for both rs4657139 (p  0.004) and
s16847548 (p 0.008). For rs10494366, the linear trend was
ot significant for QTc (p  0.209), indicating no significant
ffect of rs10494366 allele variation on QT, and both the
dditive and dominant model are equally appropriate. A
ominant model was the best fit for cardiac events (p 0.022).
he SNPs having MAF 0.10 were included in the haplo-
ypes in the following order: rs4657139 TA, rs16847548
C, and rs10494366 TG. The D= parameter and the
requency of haplotypes 0.10, defined by the unphased
enotypes and a dominant model, were estimated with the
aplo.stats R package (Mayo Foundation for Medical Educa-
ion and Research, Scottsdale, Arizona). This program uses the
xpectation-maximization algorithm to estimate the probabil-
ty of all and of the most likely haplotype combinations. The
nclusion cutoff for haplotypes was set to an estimated proba-
ility 0.80.
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June 15, 2010:2745–52 NOS1AP and Risk Stratification in LQTSenetic analysis. Genomic DNA was extracted from pe-
ipheral blood lymphocytes according to standard proce-
ures. Methods for mutation screening on LQTS genes
ave been reported in detail previously (4–6).
Multiplex-PCR amplicons were purified with exonucle-
se I–shrimp alkaline phosphatase (USB, Cleveland, Ohio)
nd used as a template for fluorescent dideoxy single-base
xtension of unlabeled oligonucleotide primers with the
BI PRISM SNaPshot Multiplex Kit (Applied Biosystems,
oster City, California). A post-extension treatment with
alf intestine alkaline phosphatase (New England BioLabs,
rankfurt, Germany), GeneScan-120 LIZ internal size
tandard addition, and heat denaturation were carried out
efore sequencing in an ABI PRISM 310 Genetic (Applied
iosystems).
tatistical analysis. Analysis of variance, paired and un-
aired t tests, and cross-tabulations with Fisher exact test
ere used as appropriate. Classification tree analysis was
sed as an explorative unbiased technique to understand the
tructure of relationships between variables and to highlight
ohort stratifications (20). We specifically used this ap-
roach in order to assess whether NOS1AP SNPs might add
nformation to risk stratification in our LQTS population
hen analyzed together with the known metrics (QTc, sex,
nd genotype). Classification trees were learned using the
range open source data mining software (University of
innesota, Duluth, Minnesota) with gain ratio as purity
easure. Correction of QTc versus NOS1AP statistics for
ultiplicity of comparisons was performed by permutation
est, and permutation-corrected p values were generated using
n adaptive permutation approach as implemented in PLINK
pen source software (Massachusetts General Hospital Center
or Human Genetic Research, Boston, Massachusetts). The
umulative probability of a first cardiac event before the age of
0 years and before antiadrenergic therapy was determined in
he entire population and in each of the 3 most prevalent
enetic loci with the use of the life-table method of Kaplan and
eier. Log-rank test with Bonferroni correction for multiplic-
ty of comparisons was applied. Cox multivariate survivorship
nalyses were performed to evaluate the significance and
ndependence of predictors of a first cardiac events or a first
ardiac arrest alone. Values of p  0.05 were considered
tatistically significant. Unless otherwise specified, analyses
ere performed using SPSS software version 16 (SPSS Inc.,
hicago, Illinois). Values of p  0.05 were considered statis-
ically significant. Means are reported  SD.
esults
he characteristics of the 901 LQTS patients (55% women,
ean age at last follow-up of 31  19 years) from 520
amilies included in the study are shown in Table 1. LQTS
ene mutations were identified in 770 patients (85%):
CNQ1 (n  421; 55%), KCNH2 (n  243; 32%), SCN5A
n  83; 11%), KCNE1 (n  21; 2.7%), and KCNE2 (n 
; 0.3%). In the remaining 131 patients, no mutations were cound in the 5 genes. Two-hundred four patients experi-
nced cardiac events.
AF of SNPs and haplotypes. The MAF of the SNPs
s4657139 TA, rs16847548 TC, and rs10494366 TG
AF were 0.42, 0.29, and 0.45, respectively, and these were
n linkage disequilibrium (D= 0.800). Out of the 901
ubjects, NOS1AP haplotypes could be estimated with a
robability 0.80 for 887 patients with 197 events (22.2%).
he AAA, aaa, and aAa haplotypes were the only ones
resenting with 0.10 frequency (0.51, 0.26, and 0.11,
espectively). SNP MAFs and common haplotype frequen-
ies are shown in Table 1. Haplotype analysis provided no
nformation beyond what was indicated by SNP analysis
lone; thus, these data are not included here. Detailed
aplotype frequencies are reported in the online supplement
Online Table 1).
OS1AP and cardiac repolarization. SNP analysis
howed that carriers (Aa or aa) of minor alleles tagged by
NPs rs4657139 and rs16847548 had a longer QTc of 7 ms
p  0.047) and 8 ms (p  0.009), respectively, in this
ohort, whereas there was no difference in QT associated
ith the minor allele of rs10494366 (Table 2).
OS1AP and cardiac events. We assessed whether tag
NP variation in the 5==NOS1AP gene were associated with
n increased risk of cardiac events in the absence of
ntiadrenergic therapy. The percentage of symptomatic
atients was higher among rs4657139 rare allele carriers as
haracteristics of LQTS PatientsTable 1 Characteristics of LQTS Patients
LQTS patients/probands 901/520
Women 498 (55%)
Age at last follow-up (yrs) 31 19
Symptomatic patients 204 (23%)
Cardiac arrest 26 (13%)
Syncope 178 (87%)
QTc (ms) 476 46
LQT locus (gene) 770 (85%)
LQT1 (KCNQ1) 421 (55%)
LQT2 (KCNH2) 243 (32%)
LQT3 (SCN5A) 83 (11%)
LQT5 (KCNE1) 21 (2.7%)
LQT6 (KCNE2) 2 (0.3%)
Not identified LQT genotype 131 (15%)
NOS1AP SNPs MAF
rs4657139 TA 0.42
rs16847548 TC 0.29
rs10494366 TG 0.45
Haplotype frequency*
AAA 0.50
aaa 0.26
aAa 0.11
ate presented as n (%) or mean SD unless otherwise noted. No significant differences in allelic
requencies in the subgroups have been identified. *The order of the polymorphisms in the
aplotype is rs4657139 TA, rs16847548 TC, and rs10494366 TG, where uppercase letters
epresent the major alleles.
LQTS  long QT syndrome; MAF  major allele frequency; NOS1AP  nitric oxide 1 adaptor
rotein; SNP  single nucleotide polymorphism; QTc  corrected QT interval.ompared with AA homozygotes (25.2% vs. 18.0%; sex-
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NOS1AP and Risk Stratification in LQTS June 15, 2010:2745–52djusted hazard ratio [HR]: 1.38, 95% confidence interval
CI]: 1.01 to 1.86; p  0.040). Similarly, rs10494366 rare
llele carriers were more symptomatic than AA homozy-
otes (24.8% vs. 17.8%; sex-adjusted HR: 1.42, 95% CI:
.03 to 1.96; p  0.031). Patients with the rs16847548
inor allele did not show an increase in risk of cardiac
vents. Similar univariate associations between SNPs and
vents were also observed with Kaplan-Meier survival anal-
sis (Online Figs. 1 to 3).
Tc, sex, and genetic locus in LQTS. Cohort records
ere analyzed over an observation period of 23  14 years,
uring which 204 patients (23%) experienced a cardiac
vent before 40 years of age or initiation of treatment with
eta-blockers (Table 1). The mean age at first cardiac event
as 14  10 years. Syncope occurred in 178 of 204 (87%)
atients, whereas cardiac arrest occurred in the remaining
6 individuals (13%).
Among LQT1, LQT2, and LQT3 patients (n  747),
ox regression analysis showed that QTc, sex, and
enetic locus were significantly associated with clinical
utcome as previously reported (4,21). Symptomatic
atients had a longer QTc (500  48 ms, n  156 vs. 466
40 ms, n  591; p  0.0001; HR for QTc 500 ms:
.81, 95% CI: 2.02 to 3.90; p  0.0001) and were more
ikely to be female (68.5% females in the symptomatic
roup vs. 51.7% among asymptomatic cases; p  0.0001;
R for females: 1.54, 95% CI: 1.02 to 2.16; p  0.014).
enetic locus was also associated with the outcome since
QT2 and LQT3 patients had more cardiac events as
ompared with LQT1 cases (HR: 1.67, 95% CI: 1.20 to
.32; p  0.002).
OS1AP and outcome prediction in LQTS. We assessed
he value of NOS1AP genotyping as a predictor of adverse
utcomes and as a novel additional metric for risk stratification
n LQTS. To this end, we first performed classification tree
nalysis for unbiased identification of risk clusters. The results
howed that NOS1AP genotype becomes informative regard-
ng event risk only in patients with QTc 500 ms, whereas
Tc and sex dominated the model for patients with QTc
500 ms. Accordingly, Cox regression in the cohort of 901
atients showed that none of the NOS1AP SNPs is a signifi-
ant independent predictor of risk of events.
Overall, cardiac event distribution was remarkably
ifferent (p  0.002) in the 4 subgroups of patients when
urther stratified by QTc and sex: females with QTc
Tc Duration in the Overall LQTS Patient Cohorthown by NOS1AP Single SNPsTable 2 QTc Duration in the Overall LQTS Patient CohortShown by NOS1AP Single SNPs
SNP
AA a-Carriers
p ValueQTc (ms) n QTc (ms) n
rs4657139 472 44 322 479 46 579 0.047
rs16847548 472 45 455 480 46 446 0.009
rs10494366 475 47 275 477 45 626 0.486
bbreviations as in Table 1.500 ms were at highest risk of events (incidence 52%, 128), followed by a risk of 25% in males with QTc
500 ms (n  77), a risk of 21% in females with QTc
500 ms (n  370), and a risk of 13% among males with
Tc 500 ms (n  326). Kaplan-Meier analyses showed
ignificant differences of event rates in the 4 groups (Fig. 1,
nline Figs. 1 to 6).
When we focused on patients with QTc 500 ms, Cox
egression analysis identified 2 independent markers of cardiac
vents: rs10494366 genotype (HR: 1.63; 95% CI: 1.06 to 2.50;
 0.03) (Fig. 2) and female sex (HR: 1.61; 95% CI: 1.10 to
.35; p 0.01). Note that these data indicate female carriers of
he minor allele of rs10494366 have a 2.6-fold increase in risk
f arrhythmic events. Multiple regression analysis confirmed
he lack of significant interaction between QTc and
s10994366. Interestingly, when we restricted the analysis to
ardiac arrest only, there were 10 events in carriers of the
s10494366 minor allele and none in the common allele
log-rank p  0.031) (Online Fig. 7).
OS1AP and LQTS mutation. Based on the published
isk stratification schemes for LQT1, LQT2, and LQT3
atients (2,4), we investigated whether NOS1AP SNPs can
dd new insights for risk stratification in this group of
atients. Univariate analysis showed that in the 747 patients
enotyped as LQT1, LQT2, or LQT3, variant alleles in
s10494366 and rs4657139 are significantly associated with
isk of cardiac events (log-rank p  0.016 and p  0.037,
espectively). Cox multivariate analysis demonstrated that:
Figure 1 Survival According to QTc and Sex
Kaplan-Meier survival analysis showing the cumulative incidence of cardiac
events according to sex and corrected QT interval (QTc) interval duration in
long QT syndrome (LQTS) population (n  901). Females with QTc 500 ms
(black continuous line) demonstrate the worst outcome.
1
2
9
2
(
s
3
w
1
a
D
H
a
m
r
a
a
u
p
s
r
u
a
H
b
(
c
g
r
Q
i
u
a
a
b
l
p
n
d
d
s
a
c
1
d
p
o
V
b
l
N
L
i
v
t
l
r
L
r
i
d
N
m
c
a
m
t
w
c
N
a
p
d
p
c
o
n
a
t
s
2749JACC Vol. 55, No. 24, 2010 Toma´s et al.
June 15, 2010:2745–52 NOS1AP and Risk Stratification in LQTS) the rs10494366 rare allele (HR: 1.47; 95% CI: 1.02 to
.13; p  0.04); 2) LQT2 or LQT3 genotype (HR: 1.76;
5% CI: 1.25 to 2.48; p  0.001); 3) QTc 500 ms (HR:
.78; 95% CI: 1.99 to 3.85; p  0.0001); and 4) female sex
HR: 1.53; 95% CI: 1.09 to 2.16; p  0.01) were each
ignificant predictors of increased risk of cardiac events (Fig.
). No significant multivariate associations were observed
ith rs4657139 rs16847548 (rs4657139 rare allele: HR:
.27; 95% CI: 0.89 to 1.80; p  0.18; rs16847548 rare
llele: HR: 1.10; 95% CI: 0.89 to 1.51; p  0.58).
iscussion
eritability of QT interval. Dissecting how genetic vari-
tion alters the electrical substrate has been the target of
any investigations and an area of intense current
esearch. Identifying the genes that modulate QT interval
nd their effect on the occurrence of cardiac events has,
ccordingly, become one of the primary goals of molec-
lar studies of cardiac excitability. Several groups have
erformed candidate gene or genome-wide association
tudies (7,8,11,22–24) to identify genetic modifiers of
epolarization. The candidate gene approach was initially
sed with the idea that variants of ion channels causing
lso the full-blown LQTS were potential modifiers.
owever, observations based on this hypothesis have
een either inconsistent or remained unconfirmed
7,23–25). More recently, data from genome-wide asso-
Figure 2 Effect of rs10494366 Minor Allele in LQTS With
QTc <500 ms
Cox regression analysis showing the independent effect of NOS1AP
rs10494366 on cumulative events-free survival in LQTS population with QTc
500 ms. The presence of at least 1 rs10494366 minor allele confers a
1.63-fold increased risk of cardiac events as compared with major allele
homozygotes. Dashed line  n  216 of 27 events; solid line  n  480 of
92 events (19%). Abbreviations as in Figure 1.iation studies identified several variants of the NOS1AP iene that play a major role in the modulation of cardiac
epolarization (8,26,27). The link between NOS1AP and
Tc was provided first by Arking et al. (8), who
dentified SNPs associated with QT duration in the
pstream 5= regulatory region of NOS1AP. Such associ-
tion came as a surprise since this gene had not been
ssociated with cardiac electrogenesis, although it had
een implicated in schizophrenia and dystrophic muscu-
ar atrophy (28,29). NOS1AP encodes the CAPON
rotein, an adaptor molecule, which binds the neural
itric oxide (NO) synthase (Nos1) via a C-terminal PDZ
omain, with scaffold and signaling ligands (e.g., dexras,
ystrophins). Functional studies show that CAPON is a
patial controller of NO production, and it modulates
ction potential duration via an effect on Ca2 and K
urrents (30,31).
Reproducible evidence obtained in a total of more than
5,000 subjects shows that not only is QT interval
uration modulated by NOS1AP, but that naturally occurring
olymorphisms in this gene exert the strongest influence of any
f the 10 loci now known to modulate QT in humans (27).
ery recently, Kao et al. (17) showed a positive association
etween some NOS1AP SNPs with incidence of SCD in a
arge cohort of community SCD cases.
OS1AP DNA variants: from population studies to
QTS. Given this robust evidence for the role of NOS1AP,
t becomes important to assess whether the same common
ariants account for the phenotypic variability among pa-
ients with LQTS (6,32), a disease in which cardiac repo-
arization is profoundly affected by deleterious mutations. A
ecent study has suggested a role for NOS1AP in modulating
QTS phenotype in an ethnically isolated population car-
ier of A341V mutation in the KCNQ1 gene (19); however,
t is unknown whether the result also applies to carriers of
ifferent mutations and, most importantly, whether
OS1AP SNPs may be used for risk stratification. One
ajor challenge for such studies in LQTS is the difficulty of
ollecting a cohort of adequate size for which clinical data
nd DNA samples are available. With this objective in
ind, we queried the clinical database and DNA Biobank at
he Maugeri Foundation and identified 901 patients in
hom NOS1AP polymorphisms and changes in QTc and
ardiac events could be studied. We chose to screen
OS1AP polymorphisms with a MAF higher than 10%
mong those that had been previously associated with QTc
rolongation and/or increased risk of sudden death in
ifferent populations worldwide (8,17,26,27). We studied a
opulation in the drug-free state in order to avoid the
onfusing effect of therapy on outcome; as a consequence,
ur results are pertinent to the role of NOS1AP SNPs on the
atural history of LQTS.
NOS1AP rs4657139 and rs16847548 rare alleles were
ssociated with a QTc prolongation of 7 and 8 ms, respec-
ively, in this cohort. At first glance, such an effect seems
mall; however, it is within the range of the prolongation
nduced by drugs known to induce “acquired long QT
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NOS1AP and Risk Stratification in LQTS June 15, 2010:2745–52yndrome,” such as terfenadine or cisapride, drugs that have
een removed from the market by regulatory authorities
ased on an excess mortality related to an average QT
rolongation of 6 ms (33). As shown by studies performed
n different databases in the last decades, QT interval
uration is the most powerful predictor of risk of arrhythmic
vents in LQTS (3,4). Thus, NOS1AP can represent a
eaningful modifier in this disease.
OS1AP and risk of events in LQTS. To assess whether,
esides prolonging the QT interval, NOS1AP SNPs con-
ribute to modulation of susceptibility to cardiac events, we
rst used classification tree analysis that showed a significant
tratification role for NOS1AP in patients with QTc 500
s. Accordingly, Cox multivariate analysis showed that a
Tc 500 ms is the strongest predictor of events followed
y sex whereas NOS1AP SNPs had a nonsignificant asso-
iation in the entire 901 patient cohort.
On the other hand, in patients with QTc 500 ms (n 
96), we found that the minor NOS1AP rs10494366 allele
ontributes quite significantly to risk stratification (HR: 2.6)
Fig. 2). Of note, not only the rate of cardiac events (syncope
nd cardiac arrest) but also the rate of cardiac arrests (hard end
oint) was significantly higher in the carriers of the minor allele
Online Fig. 7). Unfortunately, the total number of events was
nsufficient to reach multivariate statistical significance.
The new finding that variants in the NOS1AP region
ignal potential for increased risk of cardiac events and
ardiac arrest in patients with QTc 500 ms has significant
Figure 3 LQTS Risk Stratification Scheme
Combined hazard ratios (HRs) from Cox regression model identifies risk categories
clinical and genetic profile. To calculate the combined HR, we multiplied the HR of
following reference category (HR  1) and the following features: LQT1, males, QT
the combined HR for the category “LQT1, Males, QTc 500 ms, carriers of minor
Male corresponds to HR  1, QTc 500 ms corresponds to HR 2.78, and carrier
is, therefore, 1  1  2.78  1.47  4.08 as shown in the corresponding upper
with QTc 500 ms homozygous for the rs10494366 common allele (“TT”). Abbrevpidemiological and clinical implications as this group of aatients represent between 65% and 75% of the total
opulation (3,34). The more pronounced effect in patients
ith QTc 500 ms is conceivable since the risk of events is
lready so high in patients with longer QTc that it is
nlikely that the presence of a single SNP can substantially
odulate the risk.
The observation here that NOS1AP rs10494366 minor
llele has not been associated with risk of arrhythmias or
udden death in other investigations (17) is reminiscent
f findings regarding positional variation in different
ndividual NOS1AP SNP associations reported in prior
tudies on other populations (8,10,11,26,27,35). As sug-
ested by Kao et al. (17), genotyped SNPs may be
onsidered proxy measures that are exposed to variable
trength of the association with QT interval and SCD
ndependently due to unequal linkage to the actual causal
llelic variants. Therefore, we consider our finding on
s10494366 likely reflects population-specific (36) and/or
isease-specific factors, as well as the possibility that
here may be multiple functional elements within the
OS1AP region. This latter concept, if validated exper-
mentally, would also be consistent with the presence of
arkers for increased risk of arrhythmic events indepen-
ent from NOS1AP effects on QTc (17).
Based on the risk stratification model that we proposed in
003 (4), which is now part of recommended practice
uidelines for treatment of these patients (2), we analyzed
ur data to assess whether consideration of NOS1AP vari-
LQTS population. Each box shows the combined HR for patients with different
independent predictor of events derived from Cox multivariate analysis with the
ms homozygous for the common allele of NOS1AP rs10494366. Accordingly
of NOS1AP rs10494366” is calculated as follows: LQT1 corresponds to HR  1,
or allele of NOS1AP rs10494366 correspond to HR  1.47. The combined HR
orner orange box in the figure. Reference category is represented by Males LQT1
s as in Figure 1.in the
each
500
allele
of min
left c
iationtion would provide additional strength to that model. As
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June 15, 2010:2745–52 NOS1AP and Risk Stratification in LQTShown in Figure 3, genotyping variation in the NOS1AP
ene has much potential to expand event risk stratification
or many previously identified LQT1, LQT2, and LQT3
atients.
ractical implications. Although our findings will have to
e replicated in an independent LQTS population before
heir clinical use is proposed, it is possible to comment on
he potential role of NOS1AP SNPs in treating LQTS
atients.
When clinicians have to decide on therapy for LQTS
atients, the dilemma of deciding whether the patient may
eed an implantable defibrillator, besides receiving beta-
lockers, should be based on risk stratification schemes
erived from validated epidemiological studies. We previ-
usly showed (4) that QT interval, sex, and genetic locus are
he most important determinants of risk in LQT1, LQT2,
nd LQT3. Now, we provide evidence suggesting that
OS1AP SNP genotype may be a novel metric, which could
elp to refine risk stratification. This approach has particular
otential to identify individuals at higher risk among those
ith QTc 500 ms; until now, these patients, who repre-
ent the majority of LQTS clinical diagnoses, have been
rouped in a lower-risk category. It is thus possible that the
ntroduction of the screening for NOS1AP SNPs may help
he clinicians to identify subset of “QTc 500 ms patients”
t higher risk, a supposition which will have to be validated
y additional studies.
The potential of the discovery that NOS1AP variant
enotypes may have validity towards this goal is illus-
rated in Figure 3. Based on the results of others, and our
wn (4) prior findings as extended here, we would
onsider that patients with a HR 6 be further evaluated
s potential high-risk individuals who may benefit from
CD implantation. Patients with a HR between 4 and 6,
epending on other clinical variables, may also be appro-
riate ICD candidates, whereas patients with a HR 4 in
he absence of other risk factors (e.g., coronary or
tructural compromise) may be best treated with beta-
lockers, again considering other cardiac risks and best
linical practices. Such considerations should obviously
e in full compliance with clinical recommendations
ithin the current American College of Cardiology,
merican Heart Association, and the European Society
f Cardiology guidelines (2).
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olecular Cardiology Laboratories, IRCCS Fondazione Salvatore
augeri, Via Maugeri 10/10A, 27100 Pavia, Italy. E-mail:
ilvia.priori@fsm.it.
EFERENCES
1. Priori SG, Napolitano C, Schwartz PJ, et al. Genetics of cardiac
arrhythmias. In: Braunwald E, Zipes DP, Libby P, editors. Braun-
wald’s Heart Disease: A Textbook of Cardiovascular Medicine. Phil-
adelphia, PA: Elsevier Saunders, 2004:689–95.2. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006
guidelines for management of patients with ventricular arrhythmias
and the prevention of sudden cardiac death: a report of the American
College of Cardiology/American Heart Association Task Force and
the European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Develop Guidelines for Management of
Patients With Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death). J Am Coll Cardiol 2006;48:e247–346.
3. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome.
Prospective longitudinal study of 328 families. Circulation 1991;84:
1136–44.
4. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the
long-QT syndrome. N Engl J Med 2003;348:1866–74.
5. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT
syndrome loci and cardiac events among patients treated with beta-
blockers. JAMA 2004;292:1341–4.
6. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the
long QT syndrome: development and validation of an efficient ap-
proach to genotyping in clinical practice. JAMA 2005;294:2975–80.
7. Bezzina CR, Verkerk AO, Busjahn A, et al. A common polymorphism
in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res
2003;59:27–36.
8. Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the
NOS1 regulator NOS1AP modulates cardiac repolarization. Nat
Genet 2006;38:644–51.
9. Newton-Cheh C, Guo CY, Wang TJ, O’Donnell CJ, Levy D, Larson
MG. Genome-wide association study of electrocardiographic and
heart rate variability traits: the Framingham Heart Study. BMC Med
Genet 2007;8 Suppl 1:S7.
0. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, et al. Common
NOS1AP variants are associated with a prolonged QTc interval in the
Rotterdam Study. Circulation 2007;116:10–6.
1. Post W, Shen H, Damcott C, et al. Associations between genetic
variants in the NOS1AP (CAPON) gene and cardiac repolarization in
the old order Amish. Hum Hered 2007;64:214–9.
2. Lehtinen AB, Newton-Cheh C, Ziegler JT, et al. Association of
NOS1AP genetic variants with QT interval duration in families from
the Diabetes Heart Study. Diabetes 2008;57:1108–14.
3. Tobin MD, Kahonen M, Braund P, et al. Gender and effects of a
common genetic variant in the NOS1 regulator NOS1AP on cardiac
repolarization in 3761 individuals from two independent populations.
Int J Epidemiol 2008;37:1132–41.
4. Raitakari OT, Blom-Nyholm J, Koskinen TA, Kahonen M, Viikari
JS, Lehtimaki T. Common variation in NOS1AP and KCNH2 genes
and QT interval duration in young adults. The Cardiovascular Risk in
Young Finns Study. Ann Med 2009;41:144–51.
5. Marjamaa A, Newton-Cheh C, Porthan K, et al. Common candidate
gene variants are associated with QT interval duration in the general
population. J Intern Med 2009;265:448–58.
6. Eijgelsheim M, Aarnoudse AL, Rivadeneira F, et al. Identification of
a common variant at the NOS1AP locus strongly associated to
QT-interval duration. Hum Mol Genet 2009;18:347–57.
7. Kao WH, Arking DE, Post W, et al. Genetic variations in nitric
oxide synthase 1 adaptor protein are associated with sudden cardiac
death in US white community-based populations. Circulation
2009;119:940 –51.
8. Spooner PM. Sudden cardiac death: the larger problem. . .the larger
genome. J Cardiovasc Electrophysiol 2009;20:585–96.
9. Schwartz PJ, Monti MC, Insolia R, et al. NOS1AP is a genetic
modifier of the long-QT syndrome. Circulation 2009;120:1657–63.
0. Breiman LF, Friedman JH, Olshen RA, Stone CJ. Classification and
Regression Trees. New York, NY: Chapman & Hall, 1994.
1. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on
the clinical course of the long-QT syndrome. International
Long-QT Syndrome Registry Research Group. N Engl J Med
1998;339:960 –5.
2. Sesti F, Abbott GW, Wei J, et al. A common polymorphism
associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad
Sci U S A 2000;97:10613–8.
3. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease
genes in patients with drug-associated torsades de pointes. Circulation
2002;105:1943–8.
22
2
2
2
2
3
3
3
3
3
3
3
K
n
F
2752 Toma´s et al. JACC Vol. 55, No. 24, 2010
NOS1AP and Risk Stratification in LQTS June 15, 2010:2745–524. Pfeufer A, Jalilzadeh S, Perz S, et al. Common variants in myocardial
ion channel genes modify the QT interval in the general population:
results from the KORA study. Circ Res 2005;96:693–701.
5. Gouas L, Nicaud V, Berthet M, et al. Association of KCNQ1,
KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval
length in a healthy population. Eur J Hum Genet 2005;13:1213–22.
6. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants
at ten loci influence QT interval duration in the QTGEN Study. Nat
Genet 2009;41:399–406.
7. Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci
modulate the QT interval duration in the QTSCD Study. Nat Genet
2009;41:407–14.
8. Suzuki N, Motohashi N, Uezumi A, et al. NO production results in
suspension-induced muscle atrophy through dislocation of neuronal
NOS. J Clin Invest 2007;117:2468–76.
9. Eastwood SL. Does the CAPON gene confer susceptibility to schizo-
phrenia? PLoS Med 2005;2:e348.
0. Chang KC, Barth AS, Sasano T, et al. CAPON modulates cardiac
repolarization via neuronal nitric oxide synthase signaling in the heart.
Proc Natl Acad Sci U S A 2008;105:4477–82.
1. Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH.
CAPON: a protein associated with neuronal nitric oxide synthase that
regulates its interactions with PSD95. Neuron 1998;20:115–24. p2. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of
symptoms and QT intervals in carriers of the gene for the long-QT
syndrome. N Engl J Med 1992;327:846–52.
3. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation
between terfenadine (Seldane) and the QTc interval on the scalar
electrocardiogram: distinguishing a drug effect from spontaneous
variability. Am Heart J 1996;131:472–80.
4. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences
in clinical manifestations in patients with congenital long-QT syn-
drome: findings from the International LQTS Registry. Circulation
1998;97:2237–44.
5. Eijgelsheim M, Newton-Cheh C, Aarnoudse AL, et al. Genetic
variation in NOS1AP is associated with sudden cardiac death: evi-
dence from the Rotterdam Study. Hum Mol Genet 2009;18: 4213–8.
6. Novembre J, Johnson T, Bryc K, et al. Genes mirror geography within
Europe. Nature 2008;456:98–101.
ey Words: cardiac arrhythmias y long QT syndrome y single
ucleotide polymorphisms y genetics y risk stratification.
APPENDIX
or a supplemental table and figures,
lease see the online version of this article.
